Immutep announces results from Cohort B of TACTI-003 trial

Immutep (IMMP) announces positive clinical results from Cohort B of the TACTI-003 Phase IIb trial. This study evaluates eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA in first line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. Data as of the 31 October 2024 cut-off date in evaluable 1L HNSCC patients whose tumours express PD-L1 below 1 and who typically do not respond well to anti-PD-1 therapy alone shows: Positively, median overall survival has not yet been reached and the 12-month OS rate is 67%; Promising progression-free survival of 5.8 months; Strong durability with interim median duration of response of 9.3 months; High 35.5% objective response rate and 58.1% disease control rate, as reported on 12 July; Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively; Efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals